Santhera Pharmaceuticals Holding 将来の成長

Future 基準チェック /66

Santhera Pharmaceuticals Holding利益と収益がそれぞれ年間35.4%と26.8%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に48.6% 31.4%なると予測されています。

主要情報

35.4%

収益成長率

31.4%

EPS成長率

Biotechs 収益成長	37.0%
収益成長率	26.8%
将来の株主資本利益率	48.6%
アナリストカバレッジ	Low
最終更新日	27 Sep 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

LSE:0QN1 - アナリストの将来予測と過去の財務データ ( )CHF Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	135	53	61	61	1
12/31/2025	48	-10	-6	-6	2
12/31/2024	24	-35	-32	-32	2
6/30/2024	114	63	24	47	N/A
3/31/2024	109	59	24	47	N/A
12/31/2023	103	55	24	47	N/A
9/30/2023	54	-5	-7	7	N/A
6/30/2023	5	-65	-37	-33	N/A
3/31/2023	6	-68	-35	-32	N/A
12/31/2022	7	-71	-34	-30	N/A
9/30/2022	4	-68	-32	-30	N/A
6/30/2022	0	-65	-31	-31	N/A
3/31/2022	-1	-60	-34	-34	N/A
12/31/2021	-2	-56	-37	-37	N/A
9/30/2021	5	-56	-40	-40	N/A
6/30/2021	12	-56	-42	-42	N/A
3/31/2021	13	-62	-43	-43	N/A
12/31/2020	15	-68	-44	-44	N/A
9/30/2020	40	-46	-20	-20	N/A
6/30/2020	65	-24	3	3	N/A
3/31/2020	70	-21	3	3	N/A
12/31/2019	75	-19	2	3	N/A
9/30/2019	55	-37	-34	-14	N/A
6/30/2019	34	-54	-56	-36	N/A
3/31/2019	33	-54	-58	-37	N/A
12/31/2018	32	-54	-60	-38	N/A
9/30/2018	30	-58	-43	-41	N/A
6/30/2018	28	-56	-45	-42	N/A
3/31/2018	26	-54	N/A	-41	N/A
12/31/2017	23	-52	N/A	-40	N/A
9/30/2017	22	-42	N/A	-39	N/A
6/30/2017	23	-40	N/A	-33	N/A
3/31/2017	21	-38	N/A	-30	N/A
12/31/2016	19	-35	N/A	-27	N/A
9/30/2016	15	-21	N/A	-28	N/A
6/30/2016	10	-6	N/A	-29	N/A
3/31/2016	7	0	N/A	-25	N/A
12/31/2015	4	6	N/A	-22	N/A
9/30/2015	4	-3	N/A	-17	N/A
6/30/2015	3	-11	N/A	-11	N/A
3/31/2015	3	-10	N/A	-8	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	2	-7	N/A	-6	N/A
6/30/2014	1	-6	N/A	-5	N/A
3/31/2014	1	-6	N/A	-6	N/A
12/31/2013	1	-6	N/A	-7	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0QN1の予測収益成長率 (年間35.4% ) は貯蓄率 ( 2.1% ) を上回っています。

収益対市場: 0QN1の収益 ( 35.4% ) はUK市場 ( 14.6% ) よりも速いペースで成長すると予測されています。

高成長収益: 0QN1の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 0QN1の収益 ( 26.8% ) UK市場 ( 3.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0QN1の収益 ( 26.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0QN1の自己資本利益率は、3年後には非常に高くなると予測されています ( 48.6 %)。

Santhera Pharmaceuticals Holding 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Recent updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

New minor risk - Market cap size

Less than half of directors are independent

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Insufficient new directors

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Forecast to breakeven in 2024

Insufficient new directors

Forecast to breakeven in 2024

Insufficient new directors

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company

Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2020 Final Results on Apr 27, 2021

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development

New 90-day low: CHF2.98

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone

New 90-day low: CHF6.21

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy